GlassScriptPhysician profile
Yujie Shui
NPI 1891352647
$3,748.20
in general payments reported to CMS, 2019-2025
39 companies · $1,622 in 2025
The $1,622 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $429 · 2023: $851 · 2024: $846 · 2025: $1,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,319.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $502.67 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $256.16 | 2023-2025 | Jot Dx, Octrode, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.70 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $240.10 | 2023-2025 | Repatha, Otezla, Evenity |
| Sumitomo Pharma America, INC. | $234.87 | 2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $211.40 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $192.33 | 2022-2025 | |
| Abbvie INC. | $191.21 | 2022-2024 | Vraylar, Qulipta |
| Lilly USA, LLC | $190.83 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Astellas Pharma US INC | $160.83 | 2024-2025 | Veozah |
| Novo Nordisk INC | $127.46 | 2022-2025 | Ozempic, Rybelsus |
| Medtronic, INC. | $118.96 | 2024-2025 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.83 | 2023-2025 | Xifaxan, Trulance |
| Intuitive Surgical, INC. | $83.55 | 2023 | Da Vinci Surgical System |
| Heartflow, INC. | $74.46 | 2024 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $62.86 | 2022-2025 | Capvaxive, Gardasil 9 |
| Edwards Lifesciences Corporation | $61.52 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Bayer Healthcare Pharmaceuticals INC. | $61.26 | 2022-2023 | |
| Abiomed | $53.67 | 2023 | Impella |
| Corcept Therapeutics | $51.35 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $48.79 | 2024-2025 | Voquezna |
| Dexcom, INC. | $45.74 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $39.52 | 2023-2024 | Cologuard Collection Kit |
| Scilex Pharmaceuticals INC. | $34.78 | 2023 | Ztlido |
| Nevro Corp. | $33.77 | 2023 | Senza |
| Novartis Pharmaceuticals Corporation | $33.66 | 2023 | |
| Inspire Medical Systems, INC. | $32.77 | 2025 | Inspire |
| Boston Scientific Corporation | $30.70 | 2023 | Watchman Access System |
| Janssen Pharmaceuticals, INC | $27.61 | 2023 | Xarelto |
| Eisai INC. | $27.22 | 2024 | |
| Xeris Pharmaceuticals, INC. | $24.35 | 2024 | Keveyis |
| Cmp Pharma, INC. | $24.09 | 2024 | Norliqva, Atorvaliq, Liqrev |
| Aimmune Therapeutics, INC. | $22.69 | 2025 | Zenpep |
| Organogenesis INC. | $21.89 | 2025 | Puraply Wound Matrix |
| Tanabe Pharma America, INC. | $17.94 | 2023 | |
| Painteq LLC | $17.25 | 2024 | Painteq |
| Vanda Pharmaceuticals INC. | $17.06 | 2022 | |
| Axonics, INC. | $15.87 | 2024 | Axonics |
| Inogen, INC. | $13.48 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yujie Shui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.